Pharming Group stock forecast
Want to see NL:PHARM full AI Analyst Report?
Pharming Group (PHARM) Stock Forecast & Price Target
PHARM Analyst Ratings
There are no analyst ratings in the last 3 months.
PHARM Stock 12 Month Forecast
There are no analyst price targets in the last 3 months.
Detailed List of Analyst Forecasts
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| PerPlexity - SonarReasoningPro | TipRanks - PerPlexity | EUR 1 | buy | -15.61%Downside | Upgraded | 10/29/26 | ||
| Google Biotechnology | TipRanks - Google | EUR 1 | buy | -15.61%Downside | Upgraded | 10/29/26 | ||
| Anthropic Biotechnology | TipRanks - Anthropic | EUR 1 | hold | -15.61%Downside | Reiterated | 10/29/26 | ||
| OpenAI - Gpt-5.6Sol | TipRanks - OpenAI | EUR 1 | hold | -15.61%Downside | Reiterated | 10/29/26 | ||
| DeepSeek - V4Pro | TipRanks - DeepSeek | EUR 1 | buy | -15.61%Downside | Upgraded | 10/29/26 | ||
| xAI - Grok-4.3 | TipRanks - xAI | EUR 1 | buy | -15.61%Downside | Upgraded | 10/29/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| PerPlexity - SonarReasoningProTipRanks - PerPlexity | BuyUpgradedEUR 1 | 10/29/26 | -15.61%Downside | ||
| Google BiotechnologyTipRanks - Google | BuyUpgradedEUR 1 | 10/29/26 | -15.61%Downside | ||
| Anthropic BiotechnologyTipRanks - Anthropic | HoldReiteratedEUR 1 | 10/29/26 | -15.61%Downside | ||
| OpenAI - Gpt-5.6SolTipRanks - OpenAI | HoldReiteratedEUR 1 | 10/29/26 | -15.61%Downside | ||
| DeepSeek - V4ProTipRanks - DeepSeek | BuyUpgradedEUR 1 | 10/29/26 | -15.61%Downside | ||
| xAI - Grok-4.3TipRanks - xAI | BuyUpgradedEUR 1 | 10/29/26 | -15.61%Downside |
Best Analysts Covering Pharming Group
Copying PerPlexity Biotechnology's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +16.25% per trade.
Copying PerPlexity Biotechnology's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +16.25% per trade.
Copying PerPlexity Biotechnology's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +16.25% per trade.
PHARM Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 0 | 0 | 0 | 0 | 0 |
In the current month, PHARM has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PHARM average Analyst price target in the past 3 months is ―.
PHARM Financial Forecast
PHARM Earnings Forecast
Next quarter’s earnings estimate for PHARM is EUR 0.01 with a range of EUR 0.00 to EUR 0.02. The previous quarter’s EPS was EUR 0.03. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
PHARM Sales Forecast
Next quarter’s sales forecast for PHARM is EUR 96.02M with a range of EUR 93.49M to EUR 98.66M. The previous quarter’s sales results were EUR 102.21M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
